EUVIMEDEUVIMED entdecken
Crossref

Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models

J. Teh, C. Kuhlberg, K. Davenport, J. Pizzano, A. Fathizadeh, E. Masson, X. Wang

European Journal of Cancer · 2026-11 · 248 · 117699

DOI: 10.1016/j.ejca.2026.117699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von J. Teh und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Teh, J., Kuhlberg, C., Davenport, K., Pizzano, J., Fathizadeh, A., Masson, E., & Wang, X. (2026). Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models. European Journal of Cancer, 248, 117699. https://doi.org/10.1016/j.ejca.2026.117699

Vancouver

Teh J, Kuhlberg C, Davenport K, Pizzano J, Fathizadeh A, Masson E, et al. Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models. European Journal of Cancer. 2026;248:117699. doi:10.1016/j.ejca.2026.117699

BibTeX
@article{Teh2026,
  author = {Teh, J. and Kuhlberg, C. and Davenport, K. and Pizzano, J. and Fathizadeh, A. and Masson, E. and Wang, X.},
  title = {Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117699},
  doi = {10.1016/j.ejca.2026.117699}
}
Kostenlos starten →